<DOC>
	<DOCNO>NCT01194063</DOCNO>
	<brief_summary>Use fish oil emulsion decrease liver disease due long term intravenous nutrition .</brief_summary>
	<brief_title>Use Omegaven Fish Oil Emulsion Parenteral Nutrition Associated Liver Disease Infants Children</brief_title>
	<detailed_description>Unlike conventional intravenous fat emulsion , Omegaven™ comprise solely fish oil contain primarily omega-3 fatty acid . Animal study show IV fat emulsion fish oil high eicosapentaenic docosahexaenoic acid reduce impairment bile flow see cholestasis cause conventional fat emulsion . It think administer Omegaven™ place conventional phytosterol/soybean fat emulsion , cholestasis may prevent reversed , patient able maintained adequate PN growth able ingest adequate nutrition enterally . Ongoing study address safety efficacy Omegaven™ pediatric population . In trial , infant child parenteral nutrition associate liver disease receive Omegaven™ compassionate use potentially prevent progression disease . Safety efficacy monitor .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<criteria>direct bilirubin &gt; 2 mg/dl x2 consecutive parenteral nutrition dependent , expect continue least another 30 day first day patient must utilize standard therapy prevent progression liver disease primary cause liver disease parenteral nutritionassociated weight &lt; 3 kg infant child enrol clinical trial involve investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>short bowel syndrome</keyword>
	<keyword>parenteral nutrition associate liver disease</keyword>
	<keyword>pediatric</keyword>
</DOC>